News articles about ABAXIS (NASDAQ:ABAX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ABAXIS earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.2207473963361 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Shares of ABAXIS (ABAX) traded down 0.09% during midday trading on Wednesday, reaching $45.64. The company’s stock had a trading volume of 94,722 shares. ABAXIS has a 12-month low of $44.12 and a 12-month high of $55.95. The firm has a market capitalization of $1.04 billion, a P/E ratio of 32.23 and a beta of 0.81. The stock has a 50-day moving average of $48.74 and a 200 day moving average of $49.17.

ABAXIS (NASDAQ:ABAX) last announced its quarterly earnings data on Thursday, July 27th. The medical research company reported $0.28 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.33 by $0.05. ABAXIS had a net margin of 14.12% and a return on equity of 10.85%. The company had revenue of $58.26 million during the quarter, compared to analyst estimates of $60.37 million. During the same quarter last year, the business earned $0.30 EPS. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. Equities research analysts predict that ABAXIS will post $1.13 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, September 1st will be paid a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 1.23%. The ex-dividend date of this dividend is Wednesday, August 30th. ABAXIS’s dividend payout ratio (DPR) is 39.72%.

A number of equities research analysts have issued reports on ABAX shares. Aegis started coverage on ABAXIS in a research note on Friday, June 9th. They issued a “hold” rating and a $56.50 price target for the company. Zacks Investment Research upgraded ABAXIS from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 28th. Stifel Nicolaus reiterated a “hold” rating and issued a $48.00 price target on shares of ABAXIS in a research note on Friday, July 14th. BidaskClub lowered ABAXIS from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 3rd. Finally, Bank of America Corporation reiterated an “underperform” rating and issued a $42.00 price target on shares of ABAXIS in a research note on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $48.63.

TRADEMARK VIOLATION NOTICE: “ABAXIS (ABAX) Given News Sentiment Score of 0.14” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at

ABAXIS Company Profile

Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.

Insider Buying and Selling by Quarter for ABAXIS (NASDAQ:ABAX)

Receive News & Ratings for ABAXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABAXIS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.